# A Study to Investigate Safety, Tolerability, and Pharmacokinetics of Oral AZD0233 Compared With Placebo in Healthy Adult Participants.

> **NCT06381466** · PHASE1 · TERMINATED · sponsor: **AstraZeneca** · enrollment: 84 (actual)

## Conditions studied

- Dilated Cardiomyopathy

## Interventions

- **DRUG:** AZD0233
- **DRUG:** AZD0233 Placebo

## Key facts

- **NCT ID:** NCT06381466
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-04-01
- **Primary completion:** 2025-12-30
- **Final completion:** 2025-12-30
- **Target enrollment:** 84 (ACTUAL)
- **Why stopped:** The study has been terminated due to adverse finding in a non-clinical, chronic toxicology study.
- **Last updated:** 2026-01-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06381466

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06381466, "A Study to Investigate Safety, Tolerability, and Pharmacokinetics of Oral AZD0233 Compared With Placebo in Healthy Adult Participants.". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06381466. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*